explore -WSS

explore

author：leisure time 2025-09-30 00:47:24 - browse：74

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： What is microchimerism and how does it affect maternal health?

WSS

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Kidney transplant patients stopped immunosuppressants in trial

Key Senate panel to consider PBM, drug pricing reform package

How neuroscience research could help beat back brain cancer

Why does health care cost so much? A reading guide

hotspot

explore

explore

In age of alternative facts, a scholarly course on calling out crap

The health care issue Democrats can’t solve: hospital reform

Trump demands the U.S. pay no more for drugs than other countries … again

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Wildfire smoke exposes gaps in outdoor worker protections

UnitedHealth financials solid despite Change Healthcare cyberattack

The cancer drug shortage isn’t new — and neither are the solutions

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Novavax promises a turnaround & Lilly roils the obesity market

MassMutual is introducing free genetic testing for members

entertainment

Inari Medical to buy amputation prevention company LimFlow

Cue Health's Covid

Bill would allow buprenorphine prescription for addiction via telehealth

Cell therapy fails to slow type 1 diabetes, but safety is established

Diversity in clinical trials starts with building trust, experts say

Medical bills so high, Medicare adding extra digits to claim forms

focus

entertainment

Wikipedia

Wikipedia